Confronting carbapenemase-producing Klebsiella pneumoniae

Future Microbiology

Volumn 8, Issue 9, 2013, Pages 1147-1161

  Markogiannakis, Antonis ^a   Tzouvelekis, Leonidas S ^b   Psichogiou, Mina ^b   Petinaki, Efi ^c   Daikos, George L ^b  

^a LAIKO GENERAL HOSPITAL   (Greece)

^b UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^c UNIVERSITY OF THESSALY   (Greece)

Author keywords

antibiotic combinations; antibiotic resistance; antimicrobial therapy; carbapenemases; epidemiology; infection control; Klebsiella pneumoniae; novel antimicrobials

Indexed keywords

ANTIINFECTIVE AGENT; CARBAPENEMASE; CEFALOTIN; CEFOTAXIME; CEFTAZIDIME; IMIPENEM; MEROPENEM; PENICILLIN G;

CARBAPENEMASE PRODUCING MULTIDRUG RESISTANT ENTEROBACTERIA; CLINICAL PRACTICE; CLONE; COMMUNITY; ENTEROBACTERIACEAE; EPIDEMIC; HOSPITAL INFECTION; HUMAN; KLEBSIELLA PNEUMONIAE; NONHUMAN; PANDEMIC; PRIORITY JOURNAL; REVIEW;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BETA-LACTAMASES; CROSS INFECTION; DRUG DISCOVERY; DRUG RESISTANCE, MULTIPLE, BACTERIAL; HUMANS; INFECTION CONTROL; KLEBSIELLA INFECTIONS; KLEBSIELLA PNEUMONIAE;

EID: 84884142272     PISSN: 17460913     EISSN: 17460921     Source Type: Journal    
DOI: 10.2217/fmb.13.71     Document Type: Review

References (103)

1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin. Microbiol. Rev. 25(4), 682-707 (2012).
2. Nordmann P, Dortet L, Poirel L. Carbapenem resistance in Enterobacteriaceae: here is the storm! Trends Mol. Med. 18(5), 263-272 (2012).
3. Cantón R, Akova M, Carmeli Y et al. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin. Microbiol. Infect. 18(5), 413-431 (2012).
4. Hirsch EB, Tam VH. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection. J. Antimicrob. Chemother. 65(6), 1119-1125 (2010).
5. Akova M, Daikos GL, Tzouvelekis L, Carmeli Y. Interventional strategies and current clinical experience with carbapenemase-producing Gram-negative bacteria. Clin. Microbiol. Infect. 18(5), 439-448 (2012).
6. Lee GC, Burgess DS. Treatment of Klebsiella pneumoniae carbapenemase (KPC) infections: a review of published case series and case reports. Ann. Clin. Microbiol. Antimicrob. 11, 32 (2012).
7. Daikos GL, Markogiannakis A. Carbapenemase-producing Klebsiella pneumoniae: (when) might we still consider treating with carbapenems? Clin. Microbiol. Infect. 17(8), 1135-1141 (2011).
8. Daikos GL, Petrikkos P, Psichogiou M et al. Prospective observational study of the impact of VIM-1 metallo-b-lactamase on the outcome of patients with Klebsiella pneumoniae bloodstream infections. Antimicrob. Agents Chemother. 53(5), 1868-1873 (2009).
9. Qureshi ZA, Paterson DL, Potoski BA et al. Treatment outcome of bacteremia due to KPC-producing Klebsiella pneumoniae: superiority of combination antimicrobial regimens. Antimicrob. Agents Chemother. 56(4), 2108-2113 (2012).
10. Tumbarello M, Viale P, Viscoli C et al. Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: Importance of combination therapy. Clin. Infect. Dis. 55(7), 943-950 (2012).
11. Yigit H, AM Queenan JK Rasheed et al. Carbapenem-resistant strain of Klebsiella oxytoca harboring carbapenem-hydrolyzing b-lactamase KPC-2. Antimicrob. Agents Chemother. 47, 3881-3889 (2003).
12. Alba J, Ishii Y, Thomson K, Moland ES, Yamaguchi K. Kinetics study of KPC-3, a plasmid-encoded class A carbapenem-hydrolyzing beta-lactamase. Antimicrob. Agents Chemother. 49(11), 4760-4762 (2005).
13. Ke W, Bethel CR, Thomson JM, Bonomo RA, van den Akker F. Crystal structure of KPC-2: insights into carbapenemase activity in class A b-lactamases. Biochemistry 46(19), 5732-5740 (2007).
14. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: twenty-first informational supplement. CLSI document M100-S21. Clinical and Laboratory Standards Institute, Wayne, PA, USA (2011).
15. Bebrone C. Metallo-b-lactamases (classification, activity, genetic organization, structure, zinc coordination) and their superfamily. Biochem. Pharmacol. 74(12), 1686-1701 (2007).
16. Palzkill T. Metallo-b-lactamase structure and function. Ann. N. Y. Acad. Sci. 1277, 91-104 (2012).
17. Poirel L, Héritier C, Tolün V, Nordmann P. Emergence of oxacillinase-mediated resistance to imipenem in Klebsiella pneumoniae. Antimicrob. Agents Chemother. 48(1), 15-22 (2004).
18. Poirel L, Potron A, Nordmann P. OXA-48-like carbapenemases: the phantom menace. J. Antimicrob. Chemother. 67(7), 1597-1606 (2012).
19. Livermore DM, Warner M, Mushtaq S, Doumith M, Zhang J, Woodford N. What remains against carbapenem-resistant Enterobacteriaceae? Evaluation of chloramphenicol, ciprofloxacin, colistin, fosfomycin, minocycline, nitrofurantoin, temocillin and tigecycline. Int. J. Antimicrob. Agents 37(5), 415-419 (2011).
20. Anthony KB, Fishman NO, Linkin DR, Gasink LB, Edelstein PH, Lautenbach E. Clinical and microbiological outcomes of serious infections with multidrug-resistant Gram-negative organisms treated with tigecycline. Clin. Infect. Dis. 46(4), 567-570 (2008).
21. Capone A, Giannella M, Fortini D et al. High rate of colistin resistance among patients with carbapenem-resistant Klebsiella pneumoniae infection accounts for an excess of mortality. Clin. Microbiol. Infect. 19, E23-E30 (2013).
22. Pereira PS, de Araujo CF, Seki LM, Zahner V, Carvalho-Assef AP, Asensi MD. Update of the molecular epidemiology of KPC-2-producing Klebsiella pneumoniae in Brazil: spread of clonal complex 11 (ST11, ST437 and ST340). J. Antimicrob. Chemother. 68(2), 312-316 (2013).
23. Spanu T, De Angelis G, Cipriani M et al. In vivo emergence of tigecycline resistance in multidrug-resistant Klebsiella pneumoniae and Escherichia coli. Antimicrob. Agents Chemother. 56(8), 4516-4518 (2012).
24. Bratu S, Mooty M, Nichani S et al. Emergence of KPC-possessing Klebsiella pneumoniae in Brooklyn, New York: epidemiology and recommendations for detection. Antimicrob. Agents Chemother. 49(7), 3018-3020 (2005).
25. Kitchel B, Rasheed JK, Patel JB et al. Molecular epidemiology of KPC-producing Klebsiella pneumoniae in the United States: clonal expansion of MLST sequence type 258. Antimicrob. Agents Chemother. 53(8), 3365-3370 (2009).
26. MMWR. Vital signs: carbapenem-resistant Enterobacteriaceae. MMWR Morb. Mortal. Wkly Rep. 62(9), 165-170 (2013).
27. Castanheira M, Costello AJ, Deshpande LM, Jones RN. Expansion of clonal complex 258 KPC-2-producing Klebsiella pneumoniae in Latin American hospitals: report of the SENTRY Antimicrobial Surveillance Program. Antimicrob. Agents Chemother. 56(3), 1668-1669 (2012).
28. Navon-Venezia S, Leavitt A, Schwaber MJ et al. First report on a hyperepidemic clone of KPC-3-producing Klebsiella pneumoniae in Israel genetically related to a strain causing outbreaks in the United States. Antimicrob. Agents Chemother. 53(2), 818-820 (2009).
29. Wernli D, Haustein T, Conly J, Carmeli Y, Kickbusch I, Harbarth S. A call for action: the application of The International Health Regulations to the global threat of antimicrobial resistance. PLoS Med. 8, e1001022 (2011).
30. Wendt C, Schütt S, Dalpke AH et al. First outbreak of Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in Germany. Eur. J. Clin. Microbiol. Infect. Dis. 29(5), 563-570 (2010).
31. Meessen N, Wiersinga J, van der Zwaluw K, van Altena R. First outbreak of carbapenemase-producing Klebsiella pneumoniae in a tuberculosis care facility in The Netherlands. Presented at: Proceedings of the 20th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). Vienna, Austria 10-13 April 2010 (Abstract P1283).
32. Qi Y, Wei Z, Ji S, Du X, Shen P, Yu Y. ST11, the dominant clone of KPC-producing Klebsiella pneumoniae in China. J. Antimicrob. Chemother. 66(2), 307-312 (2011).
33. Cuzon G, Naas T, Truong H et al. Worldwide diversity of Klebsiella pneumoniae that produce beta-lactamase blaKPC-2 gene. Emerg. Infect. Dis. 16(9), 1349-1356 (2010).
34. Patel G, Bonomo RA. "Stormy waters ahead": global emergence of carbapenemases. Front. Microbiol. 4, 48 (2013).
35. Richter SN, Frasson I, Franchin E et al. KPC-mediated resistance in Klebsiella pneumoniae in two hospitals in Padua, Italy, June 2009-December 2011: massive spreading of a KPC-3-encoding plasmid and involvement of non-intensive care units. Gut Pathog. 4(1), 7 (2012).
36. Carattoli A. Plasmids and the spread of resistance. Int. J Med. Microbiol. 303(6-7), 298-304 (2013).
37. Cornaglia G, Giamarellou H, Rossolini GM. Metallo-b-lactamases: a last frontier for b-lactams? Lancet Infect. Dis. 11(5), 381-393 (2011).
38. Psichogiou M, Tassios PT, Avlamis A et al. Ongoing epidemic of blaVIM-1-positive Klebsiella pneumoniae in Athens, Greece: a prospective survey. J. Antimicrob. Chemother. 61(1), 59-63 (2008).
39. Giakkoupi P, Papagiannitsis CC, Miriagou V et al. An update of the evolving epidemic of blaKPC-2-carrying Klebsiella pneumoniae in Greece (2009-2010). J. Antimicrob. Chemother. 66(7), 1510-1513 (2011).
40. Kumarasamy KK, Toleman MA, Walsh TR et al. Emergence of a new antibiotic resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. Dis. 10(9), 597-602 (2010).
41. Nordmann P, Poirel L, Toleman MA, Walsh TR. Does broad-spectrum b-lactam resistance due to NDM-1 herald the end of the antibiotic era for treatment of infections caused by Gram-negative bacteria? J. Antimicrob. Chemother. 66(4), 689-692 (2011).
42. Nordmann P, Poirel L, Walsh TR, Livermore DM. The emerging NDM carbapenemases. Trends Microbiol. 19(12), 588-595 (2011).
43. Carrër A, Poirel L, Yilmaz M et al. Spread of OXA-48-encoding plasmid in Turkey and beyond. Antimicrob. Agents Chemother. 54(3), 1369-1373 (2010).
44. European Centre for Disease Prevention and Control. Risk assessment on the spread of carbapenemase-producing Enterobacteriaceae (CPE) through patient transfer between healthcare facilities, with special emphasis on cross-border transfer. ECDC, Stockholm, Sweden (2011).
45. Nordmann P, Couard JP, Sansot D, Poirel L. Emergence of an autochthonous and community-acquired NDM-1-producing Klebsiella pneumoniae in Europe. Clin. Infect. Dis. 54(1), 150-151 (2012).
46. Kim MN, Yong D, An D et al. Nosocomial clustering of NDM-1-producing Klebsiella pneumoniae sequence type 340 strains in four patients at a South Korean tertiary care hospital. J. Clin. Microbiol. 50(4), 1433-1436 (2012).
47. Borer A, Saidel-Odes L, Eskira S et al. Risk factors for developing clinical infection with carbapenem-resistant Klebsiella pneumoniae in hospital patients initially only colonized with carbapenem-resistant K. pneumoniae. Am. J. Infect. Control 40 (5), 421-425 (2012).
48. Schechner V, Kotlovsky T, Kasma M et al. Carbapenem-resistant Enterobacteriaceae: who is prone to become clinically infected? Clin. Microbiol. Infect. 19 (5), 451-456 (2013).
49. Saidel-Odes L, Polachek H, Peled N et al. A randomized, double-blind, placebo-controlled trial of selective digestive decontamination using oral gentamicin and oral polymyxin E for eradication of carbapenem-resistant Klebsiella pneumoniae carriage. Infect. Control Hosp. Epidemiol. 33(1), 14-19 (2012).
50. Feldman N, Adler A, Molsatzki N et al. Gastrointestinal colonization by KPC-producing Klebsiella pneumoniae following hospital discharge: duration of carriage and risk factors for persistent carriage. Clin. Microbiol. Infect. 19(4) E190-E196 (2013).
51. Sypsa V, Psichogiou M, Bouzala GA, Hadjihannas L, Hatzakis A, Daikos GL. Transmission dynamics of carbapenemase-producing Klebsiella pneumoniae and anticipated impact of infection control strategies in a surgical unit. PLoS ONE 7(7), e41068 (2012).
52. CDC. Guidance for control of carbapenem-resistant Enterobacteriaceae (CRE). 2012 CRE Toolkit. CDC, Atlanta, GA, USA (2012).
53. Schwaber MJ, Lev B, Israeli A et al. Containment of a country-wide outbreak of carbapenem-resistant Klebsiella pneumoniae in Israeli hospitals via a nationally implemented intervention. Clin. Infect. Dis. 52(7), 848-855 (2011).
54. Giakkoupi P, Tzouvelekis LS, Daikos GL et al. Discrepancies and interpretation problems in susceptibility testing of VIM-1-producing Klebsiella pneumoniae isolates. J. Clin. Microbiol. 43(1), 494-496 (2005).
55. Tenover FC, Kalsi RK, Williams PP et al. Carbapenem resistance in Klebsiella pneumoniae not detected by automated susceptibility testing. Emerg. Infect. Dis. 12(8), 1209-1213 (2006).
56. Woodford N, Eastaway AT, Ford M et al. Comparison of BD phoenix, Vitek 2, and MicroScan automated systems for detection and inference of mechanisms responsible for carbapenem resistance in Enterobacteriaceae. J. Clin. Microbiol. 48(8), 2999-3002 (2010).
57. Nordmann P, Gniadkowski M, Giske CG et al. Identification and screening of carbapenemase-producing Enterobacteriaceae. Clin. Microbiol. Infect. 18(5), 432-438 (2012).
58. Avlami A, Bekris S, Ganteris G et al. Detection of metallo-b-lactamase genes in clinical specimens by a commercial multiplex PCR system. J. Microbiol. Methods 83(2), 185-187 (2010).
59. Spanu T, Fiori B, D'Inzeo T et al. Evaluation of the New NucliSENS EasyQ KPC test for rapid detection of Klebsiella pneumoniae carbapenemase genes (blaKPC). J. Clin. Microbiol. 50(8), 2783-2785 (2012).
60. Cuzon G, Naas T, Bogaerts P, Glupczynski Y, Nordmann P. Evaluation of a DNA microarray for the rapid detection of extended-spectrum b-lactamases (TEM, SHV and CTX-M), plasmid-mediated cephalosporinases (CMY-2-like, DHA, FOX, ACC-1, ACT/MIR and CMY-1-like/MOX) and carbapenemases (KPC, OXA-48, VIM, IMP and NDM). J. Antimicrob. Chemother. 67(8), 1865-1869 (2012).
61. Hrabák J, Studentová V, Walková R et al. Detection of NDM-1, VIM-1, KPC, OXA-48, and OXA-162 carbapenemases by matrix-assisted laser desorption ionization-time of flight mass spectrometry. J. Clin. Microbiol. 50(7), 2441-2443 (2012).
62. Nordmann P, Poirel L, Dortet L. Rapid detection of carbapenemase- producing Enterobacteriaceae. Emerg. Infect. Dis. 18(9), 1503-1507 (2012).
63. Gazin M, Paasch F, Goossens H, Malhotra-Kumar S; MOSAR WP2 and SATURN WP1 study teams. Current trends in culture-based and molecular detection of extended-spectrum-b-lactamase-harboring and carbapenem-resistant Enterobacteriaceae. J. Clin. Microbiol. 50(4), 1140-1146 (2012).
64. Daikos GL, Markogiannakis A, Souli M, Tzouvelekis LS. Bloodstream infections caused by carbapenemase-producing Klebsiella pneumoniae: a clinical perspective. Expert Rev. Anti Infect. Ther. 10(12), 1393-1404 (2012).
65. Hirsch EB, Guo B, Chang K-T et al. Assessment of antimicrobial combinations for KPC-producing Klebsiella pneumoniae. J. Infect. Dis. 207(5) 786-793 (2013).
66. Dudhani RV, Turnidge JD, Nation RL, Li JJ. fAUC/MIC is the most predictive pharmacokinetic/pharmacodynamic index of colistin against Acinetobacter baumannii in murine thigh and lung infection models. J. Antimicrob. Chemother. 65(9), 1984-1990 (2010).
67. Plachouras D, Karvanen M, Friberg LE et al. Population pharmacokinetic analysis of colistin methanesulfonate and colistin after intravenous administration in critically ill patients with infections caused by Gram-negative bacteria. Antimicrob. Agents Chemother. 53(8), 3430-3436 (2009).
68. Garonzik SM, Thamlikitkul V, Paterson DL et al. Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients. Antimicrob. Agents Chemother. 55(7), 3284-3294 (2011).
69. Imberti R, Cusato M, Villani P et al. Steady-state pharmacokinetics and BAL concentrations of colistin in critically ill patients after IV colistin methanesulfonate administration. Chest 38(6), 1333-1339 (2010).
70. Markou N, Fousteri M, Markantonis SL, Boutzouka E, Tsigou E, Baltopoulos G. Colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium. Chest 139(1), 232-233 (2011).
71. Daikos GL, Skiada A, Pavleas J et al. Serum bactericidal activity of three different dosing regimens of colistin with implications for optimum clinical use. J. Chemother. 22(3), 175-178 (2010).
72. Fernández L, Breidenstein EB, Hancock RE. Creeping baselines and adaptive resistance to antibiotics. Drug Resist. Updat. 14(1), 1-21 (2011).
73. Humphries RM, Kelesidis T, Dien Bard J, Ward KW, Bhattacharya D, Lewinski MA. Successful treatment of pan-resistant Klebsiella pneumoniae pneumonia and bacteraemia with a combination of high-dose tigecycline and colistin. J. Med. Microbiol. 59(11), 1383-1386 (2010).
74. Rodvold KA, Gotfried MH, Cwik M et al. Serum, tissue and body fluid concentrations of tigecycline after a single 100 mg dose. J. Antimicrob. Chemother. 58(6), 1221-1229 (2006).
75. van Duin D, Kaye KS, Neuner EA, Bonomo RA. Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn. Microbiol. Infect. Dis. 75(2), 115-120 (2013).
76. Livermore DM, Andrews JM, Hawkey PM et al. Are susceptibility tests enough, or should laboratories still seek ESBLs and carbapenemases directly? J. Antimicrob. Chemother. 67(7), 1569-1577 (2012).
77. Bulik CC, Christensen H, Li P, Sutherland CA, Nicolau DP, Kuti JL. Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob. Agents Chemother. 54(2), 804-810 (2010).
78. Bulik CC, Nicolau DP. In vivo efficacy of simulated human dosing regimens of prolonged-infusion doripenem against carbapenemase-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 54(10), 4112-4115 (2010).
79. Michalopoulos A, Virtzili S, Rafailidis P, Chalevelakis G, Damala M, Falagas ME. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation. Clin. Microbiol. Infect. 16(2), 184-186 (2010).
80. Karageorgopoulos DE, Miriagou V, Tzouvelekis LS, Spyridopoulou K, Daikos GL. Emergence of resistance to fosfomycin used as adjunct therapy in KPC Klebsiella pneumoniae bacteraemia: report of three cases. J. Antimicrob. Chemother. 67(11), 2777-2779 (2012).
81. Nilsson A, Berg OG, Aspevall O, Kahlmeter G, Andersson DI. Biological costs and mechanisms of fosfomycin resistance in Escherichia coli. Antimicrob. Agents Chemother. 47(9), 2850-2858 (2003).
82. Maherault AC, Nordmann P, Therby A, Pangon B. Efficacy of imipenem for the treatment of bacteremia due to an OXA-48-producing Klebsiella pneumoniae isolate. Clin. Infect. Dis. 54(4), 577-578 (2012).
83. Navarro-San Francisco C, Mora-Rillo M, Romero-Gómez MP et al. Bacteremia due to OXA-48-carbapenemase-producing Enterobacteriaceae: a major clinical challenge. Clin. Microbiol. Infect. 19(2), E72-E79 (2013).
84. Mimoz O, Grégoire N, Poirel L, Marliat M, Couet W, Nordmann P. Broad-spectrum b-lactam antibiotics for treating experimental peritonitis in mice due to Klebsiella pneumoniae producing the carbapenemase OXA-48. Antimicrob. Agents Chemother. 56(5), 2759-2760 (2012).
85. Livermore DM, Mushtaq S, Warner M et al. Activity of aminoglycosides, including ACHN-490, against carbapenem-resistant Enterobacteriaceae isolates. J. Antimicrob. Chemother. 66(1), 48-53 (2011).
86. Van Wart S, Bhavnanil SM, Forrest A, Bruss J, Cass R, Ambrose PG. Population pharmacokinetics of ACHN-490 injection in healthy subjects. Presented at: 48th Annual Meeting of the Infectious Diseases Society of America. Vancouver, BC, Canada, 21-24 October 2010.
87. Zhanel GG, Lawson CD, Zelenitsky S et al. Comparison of the next-generation aminoglycoside plazomicin to gentamicin, tobramycin and amikacin. Expert Rev. Anti Infect. Ther. 10(4), 459-473 (2012).
88. Page MG, Heim J. New molecules from old classes: revisiting the development of b-lactams. IDrugs 12 (9), 561-565 (2009).
89. Page MG, Dantier C, Desarbre E. In vitro properties of BAL30072, a novel siderophore sulfactam with activity against multiresistant Gram-negative bacilli. Antimicrob. Agents Chemother. 54(6), 2291-2302 (2010).
90. Miriagou V, Papagiannitsis C, Kotsakis S et al. Efficacy of BAL30072, alone and combined with meropenem, against VIM-producing enterobacteria in a murine thigh infection model. Program and Abstracts of the 20th European Congress of Clinical Microbiology and Infectious Diseases ECCMID. Vienna, Austria, 10-13 April 2010 (Poster P1240).
91. Walsh TR, Weeks J, Toleman M et al. Activity of the novel sulfactam BAL30072, alone and in combination with meropenem, against Enterobacteriaceae harbouring NDM-1 beta-lactamase. Program and Abstracts of the 21st European Congress of Clinical Microbiology and Infectious Diseases ECCMID, 27th International Congress of Chemotherapy ICC. Milan, Italy, 7-10 May 2011 (Poster P1146).
92. Stachyra T, Levasseur P, Pechereau MC et al. In vitro activity of the b-lactamase inhibitor NXL104 against KPC-2 carbapenemase and Enterobacteriaceae expressing KPC carbapenemases. J. Antimicrob. Chemother. 64(2), 326-329 (2009).
93. Endimiani A, Hujer KM, Hujer AM, Pulse ME, Weiss WJ, Bonomo RA. Evaluation of ceftazidime and NXL104 in two murine models of infection due to KPC-producing Klebsiella pneumoniae. Antimicrob. Agents Chemother. 55(1), 82-85 (2011).
94. Vazquez JA, González, Patzán LD et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr. Med. Res. Opin. 28(12), 1921-1931 (2012).
95. Young K, Raghoobar SL, Hairston NN et al. In vitro activity of the class A and C b-lactamase inhibitor MK-7655. Program and Abstracts of the 50th Interscience Conference on Antimicrobial Agents and Chemotherapy. Boston, MA, USA 12-15 September 2010 (Abstract F1-2139).
96. Hirsch EB, Ledesma KR, Chang KT, Schwartz MS, Motyl MR, Tam VH. In vitro activity of MK-7655, a novel b-lactamase inhibitor, in combination with imipenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 56(7), 3753-3757 (2012).
97. Livermore DM, Mashtaq S. Activity of biapenem (RPX2003) combined with boronate b-lactamase inhibitor RPX7009, against carbapenem-resistant Enterobacteriaceae. J. Antimicrob. Chemother. 68(8), 1825-1831 (2013).
98. Walsh TR. Emerging carbapenemases: a global perspective. Int. J. Antimicrob. Agents 36(Suppl 3), S8-S14 (2010).
99. Bush K. Improving known classes of antibiotics: an optimistic approach for the future. Curr. Opin. Pharmacol. 12(5), 527-534 (2012).
100. Zhang J, Zhang L, Li X, Xu W. UDP-3-O-(R-3-hydroxymyristoyl)-N- acetylglucosamine deacetylase (LpxC) inhibitors: a new class of antibacterial agents. Curr. Med. Chem. 19(13), 2038-2050 (2012).
101. Franceschini N, Caravelli B, Docquier JD et al. Purification and biochemical characterization of the VIM-1 metallo-b-lactamase. Antimicrob. Agents Chemother. 44(11), 3003-3007 (2000).
102. Laraki N, Franceschini N, Rossolini GM et al. Biochemical characterization of the Pseudomonas aeruginosa 101/1477 metallo-b-lactamase IMP-1 produced by Escherichia coli. Antimicrob. Agents Chemother. 43(4), 902-906 (1999).
103. Yong D, Toleman MA, Giske CG et al. Characterization of a new metallo-b-lactamase gene, blaNDM-1, and a novel erythromycin esterase gene carried on a unique genetic structure in Klebsiella pneumoniae sequence type 14 from India. Antimicrob. Agents Chemother. 53(12), 5046-5054 (2009).